PMID- 27151029
OWN - NLM
STAT- MEDLINE
DCOM- 20160915
LR  - 20181202
IS  - 1009-2137 (Print)
IS  - 1009-2137 (Linking)
VI  - 24
IP  - 2
DP  - 2016 Apr
TI  - [Clinical Summarization of Allogeneic Hematopoietic Stem Cell Transplantation for 
      Leukemia: A Report of 100 Cases].
PG  - 556-61
LID - 10.7534/j.issn.1009-2137.2016.02.047 [doi]
AB  - OBJECTIVE: To analyze the treatment outcome of a consecutive series of 100 
      leukemia patients received allogeneic hematopoietic stem cell transplantation 
      (allo-HSCT). METHODS: The clinical data of leukemia patients received allo-HSCT 
      were analyzed retrospectively, the therapeutic efficacy was summarized. 100 
      evaluable cases of leukemia included 47 cases of AML, 33 cases of ALL, 2 cases of 
      AL (biphenotypic), 16 CML and 2 CMML. Before transplantation, 76 cases were in 
      first complete remission, 9 cases in second or greater complete remission and 15 
      cases in non-remission or relapse. All the patients received peripheral blood 
      hematopoietic stem cell transplantation (PBHSCT). The conditioning regimen of 
      human leukocyte antigen (HLA)-matched allo-HSCT group was modified BuCy, but in 
      HLA-mismatched group Fludarabine and anti-human thymocyte globulin (ATG) was 
      added. CsA+MTX regimen was used for prophylaxis of graft-versus-host disease 
      (GVHD) in HLA-identical allo-HSCT, while additional MMF was added in 
      HLA-mismatched group. The average time of follow-up was 13 months. RESULTS: At 
      the last follow-up, 66.0% (66/100) patients survived, 53.0% (53/100) patients 
      survived without leukemia, 28.0% (28/100) patients relapsed and 34.0% (34/100) 
      patients died, 44.1% patients of them died from infectious pulmonary 
      complications. During transplantation, 65.0% of the patients were suffered from 
      lung infection. The overall survival (OS) and disease-free survival (DFS) of all 
      cases was 60.9% and 48.8%, respectively. The recurrence rate was significantly 
      higher in non-remission (66.7%) than in CR (21.2%) patients (P < 0.05). The 
      cumulative incidence of GVHD in HLA-mismatched transplantation was 60.8%, which 
      was significantly higher than that of HLA-matched transplantation (38.8%) (P < 
      0.05). CONCLUSION: Allo-HSCT can cure a significant proportion of leukemia 
      patients, especially for those in CR status. Since the incidence of infectious 
      pulmonary complications after allo-HSCT is still high, much more attention should 
      be paid to it. The comprehensive prognosis of HLA-matched transplantation is 
      better than the HLA-mis-matched transplantation.
FAU - Huang, Qing-Xin
AU  - Huang QX
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510280, Guangdong Province, China.
FAU - Tu, San-Fang
AU  - Tu SF
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510280, Guangdong Province, China.
FAU - Huang, Rui
AU  - Huang R
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510280, Guangdong Province, China.
FAU - Huang, Yu-Xian
AU  - Huang YX
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510280, Guangdong Province, China.
FAU - Deng, Lan
AU  - Deng L
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510280, Guangdong Province, China.
FAU - Wu, Bing-Yi
AU  - Wu BY
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510280, Guangdong Province, China.
FAU - Song, Chao-Yang
AU  - Song CY
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510280, Guangdong Province, China.
FAU - Li, Yu-Hua
AU  - Li YH
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510280, Guangdong Province, China. E-mail: liyuhua2011gz@163.com.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Shi Yan Xue Ye Xue Za Zhi
JT  - Zhongguo shi yan xue ye xue za zhi
JID - 101084424
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (HLA Antigens)
RN  - FA2DM6879K (Vidarabine)
RN  - P2K93U8740 (fludarabine)
SB  - IM
MH  - Antilymphocyte Serum/therapeutic use
MH  - Disease-Free Survival
MH  - Graft vs Host Disease/prevention & control
MH  - HLA Antigens/genetics
MH  - Humans
MH  - Incidence
MH  - Leukemia/*therapy
MH  - *Peripheral Blood Stem Cell Transplantation
MH  - Recurrence
MH  - Retrospective Studies
MH  - *Transplantation Conditioning
MH  - Treatment Outcome
MH  - Vidarabine/analogs & derivatives/therapeutic use
EDAT- 2016/05/07 06:00
MHDA- 2016/09/16 06:00
CRDT- 2016/05/07 06:00
PHST- 2016/05/07 06:00 [entrez]
PHST- 2016/05/07 06:00 [pubmed]
PHST- 2016/09/16 06:00 [medline]
AID - 1009-2137(2016)02-0556-06 [pii]
AID - 10.7534/j.issn.1009-2137.2016.02.047 [doi]
PST - ppublish
SO  - Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Apr;24(2):556-61. doi: 
      10.7534/j.issn.1009-2137.2016.02.047.